Predictive Value of Peripheral Blood Biomarkers in the Treatment of
Lung Cancer Patients with Anti PD-1 Immunotherapy.
10.3779/j.issn.1009-3419.2023.102.38
- VernacularTitle:外周血免疫指标在肺癌患者免疫治疗中的预测价值
- Author:
Shu SU
1
;
Xin LV
1
;
Liang QI
1
;
Min WEI
2
;
Baorui LIU
1
;
Lifeng WANG
1
Author Information
1. The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiated Hospital of Medical School,
Nanjing University & Clinical Center Institute of Nanjing University, 210008 Nanjing, China.
2. Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, 210008 Nanjing, China.
- Publication Type:Journal Article
- Keywords:
Biomarkers;
Efficacy prediction;
Immunotherapy;
Lung neoplasms
- MeSH:
Humans;
Lung Neoplasms/metabolism*;
Interleukin-5/therapeutic use*;
Tumor Necrosis Factor-alpha/therapeutic use*;
Retrospective Studies;
Programmed Cell Death 1 Receptor;
Biomarkers;
Immunotherapy;
Disease Progression;
B7-H1 Antigen
- From:
Chinese Journal of Lung Cancer
2024;26(12):901-909
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:The application of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibodies has greatly improved the clinical outcomes of lung cancer patients. Here, we retrospectively analyzed the efficacy of PD-1 antibody therapy in locally advanced non-surgical or metastatic lung cancer patients, and preliminarily explored the correlation between peripheral blood biomarkers and clinical responses.
METHODS:We conducted a single center study that included 61 IIIA-IV lung cancer patients who received PD-1 antibody treatment from March 2020 to December 2021, and collected the medical record data on PD-1 antibody first-line or second-line treatment. The levels of multiple Th1 and Th2 cytokines in the patient's peripheral blood serum, as well as the phenotype of peripheral blood T cells, were detected and analyzed.
RESULTS:All the patients completed at least 2 cycles of PD-1 monoclonal antibody treatment. Among them, 42 patients (68.9%) achieved partial response (PR); 7 patients (11.5%) had stable disease (SD); and 12 patients (19.7%) had progressive disease (PD). The levels of peripheral blood interferon gamma (IFN-γ) (P=0.023), tumor necrosis factor α (TNF-α) (P=0.007) and interleukin 5 (IL-5) (P=0.002) before treatment were higher in patients of the disease control rate (DCR) (PR+SD) group than in the PD group. In addition, the decrease in absolute peripheral blood lymphocyte count after PD-1 antibody treatment was associated with disease progression (P=0.023). Moreover, the levels of IL-5 (P=0.0027) and IL-10 (P=0.0208) in the blood serum after immunotherapy were significantly increased compared to baseline.
CONCLUSIONS:Peripheral blood serum IFN-γ, TNF-α and IL-5 in lung cancer patients have certain roles in predicting the clinical efficacy of anti-PD-1 therapy. The decrease in absolute peripheral blood lymphocyte count in lung cancer patients is related to disease progression, but large-scale prospective studies are needed to further elucidate the value of these biomarkers.
